Skip to content

Cerus CERS Free cash flow

Free cash flow at other companies

CorMedix logo
CorMedixCRMD
$41.65M+111%
Haemonetics logo
HaemoneticsHAE
$53.28M-47.2%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
-$67M-813%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$49.16M-139%
ADMA Biologics logo
ADMA BiologicsADMA
$55.71M+329%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Calculated from Cerus’s reported figures.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's free cash flow?
Cerus (CERS) reported free cash flow of -$3.28M in Q1 2026.
How has Cerus's free cash flow changed year-over-year?
Cerus's free cash flow decreased by 243.3% year-over-year, from -$956K to -$3.28M.
What is the long-term trend for Cerus's free cash flow?
Over 4 years (2021 to 2025), Cerus's free cash flow has grown at a -57.8% compound annual growth rate (CAGR), from -$34.83M to $1.11M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.